Yung Zip Chemical Ind. Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 09, 2022
Share
Yung Zip Chemical Ind. Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 154.65 million compared to TWD 137.05 million a year ago. Net income was TWD 33.32 million compared to TWD 12.37 million a year ago. Basic earnings per share from continuing operations was TWD 0.79 compared to TWD 0.29 a year ago. Diluted earnings per share from continuing operations was TWD 0.79 compared to TWD 0.29 a year ago. Basic earnings per share was TWD 0.79 compared to TWD 0.29 a year ago. Diluted earnings per share was TWD 0.79 compared to TWD 0.29 a year ago.
For the six months, sales was TWD 262.79 million compared to TWD 244.42 million a year ago. Net income was TWD 38.61 million compared to TWD 9.29 million a year ago. Basic earnings per share from continuing operations was TWD 0.91 compared to TWD 0.22 a year ago. Diluted earnings per share from continuing operations was TWD 0.91 compared to TWD 0.22 a year ago. Basic earnings per share was TWD 0.91 compared to TWD 0.22 a year ago. Diluted earnings per share was TWD 0.91 compared to TWD 0.22 a year ago.
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.